Overview
- Peptide (C)NRGLEDGESWEYQI, corresponding to amino acid residues 712-725 of human TRPV6 (Accession Q9H1D0). Intracellular, C-terminus.
- Human prostate cancer cell line, PC3 (1:200). It is recommended to add 0.5% Tween-20 to the antibody solution.
Western blot analysis of Human PC-3 prostate cancer cell lysate:1. Anti-TRPV6 Antibody (#ACC-036), (1:200).
2. Anti-TRPV6 Antibody, preincubated with TRPV6 Blocking Peptide (#BLP-CC036).
- Human LNCaP cells (Lallet-Daner, H. et al. (2009) Oncogene 28, 1792.).
- Rat and mouse spinal cord frozen sections.
- PC-3 cells (1:100).
TRP channels are a large family (about 28 genes) of plasma membrane, non-selective cationic channels that are either specifically or ubiquitously expressed in excitable and non-excitable cells.1 According to IUPHAR the TRP family comprises of three main subfamilies on the basis of sequence homology; TRPC, TRPM and TRPV (to date, three extra subfamilies are considered to belong to the TRP family; the TRPA, TRPML, and TRPP).1-4 The TRPV subfamily consists of six members, TRPV1-6.5
TRPV6 (CaT1) and TRPV5 (ECaC) are unique members of the TRP family. Both are epithelial calcium channels, form constitutively open channels, share high degree of homology (about 66%) with differences in the N and C-terminus. TRPV6 and TRPV5 are expressed in a 1,25-dihydroxyvitamin D3 dependent manner. In contrast to other members of the TRP family, TRPV6 and TRPV5 are highly Ca2+ selective and are expressed in Ca2+ transporting epithelia where they are assumed to have an important role in Ca2+ reabsorption. TRPV6 is highly expressed in the placenta, small intestine and kidney.6,7
While not being expressed in benign prostate tissue, TRPV6 was found to be upregulated in prostate cancer tissue and correlation between expression and tumor grade was shown. Finally, TRPV6 was suggested as prognostic marker and as a promising candidate for therapeutic strategies.8,9
Expression of TRPV6 in prostate cancer.Immunohistochemical staining of human prostate tissue using Anti-TRPV6 Antibody (#ACC-036). Very low expression of TRPV6 is observed in normal (right panel) and benign hyperplasia (middle panel) as opposed to significant expression in prostate adenocarcinoma.Adapted from Raphael, M. et al. (2014) Proc. Natl. Acad. Sci. U.S.A. 111, E3870.
